Exelixis, Inc. (NASDAQ:EXEL) Holdings Boosted by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC raised its stake in Exelixis, Inc. (NASDAQ:EXEL) by 125.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 90,858 shares of the biotechnology company’s stock after acquiring an additional 50,640 shares during the period. Exchange Traded Concepts LLC’s holdings in Exelixis were worth $3,026,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Los Angeles Capital Management LLC boosted its position in Exelixis by 124.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock valued at $46,473,000 after purchasing an additional 991,494 shares during the period. Caisse DE Depot ET Placement DU Quebec acquired a new position in shares of Exelixis during the third quarter valued at $14,979,000. AQR Capital Management LLC grew its position in shares of Exelixis by 12.7% during the second quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company’s stock worth $73,425,000 after acquiring an additional 370,199 shares during the last quarter. Burney Co. acquired a new stake in shares of Exelixis in the 4th quarter worth about $12,267,000. Finally, Robeco Institutional Asset Management B.V. lifted its position in Exelixis by 263.1% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 483,064 shares of the biotechnology company’s stock valued at $12,536,000 after purchasing an additional 350,026 shares during the last quarter. 85.27% of the stock is owned by institutional investors.

Exelixis Stock Down 5.1 %

Shares of NASDAQ EXEL opened at $32.38 on Friday. The stock’s fifty day simple moving average is $34.87 and its 200 day simple moving average is $29.77. The stock has a market capitalization of $9.25 billion, a price-to-earnings ratio of 20.76, a PEG ratio of 0.72 and a beta of 0.53. Exelixis, Inc. has a 52-week low of $20.01 and a 52-week high of $37.59.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The firm had revenue of $539.50 million for the quarter, compared to the consensus estimate of $490.31 million. During the same quarter in the previous year, the company earned $0.10 EPS. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. As a group, analysts anticipate that Exelixis, Inc. will post 1.74 earnings per share for the current year.

Insider Activity at Exelixis

In other news, EVP Jeffrey Hessekiel sold 25,000 shares of the company’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $28.39, for a total value of $709,750.00. Following the transaction, the executive vice president now owns 580,325 shares in the company, valued at $16,475,426.75. This represents a 4.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Dana Aftab sold 1,162 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total transaction of $36,486.80. Following the sale, the executive vice president now owns 498,945 shares of the company’s stock, valued at approximately $15,666,873. This represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 314,736 shares of company stock worth $10,849,110. 2.85% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have commented on EXEL shares. HC Wainwright upped their target price on shares of Exelixis from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Piper Sandler raised their target price on Exelixis from $36.00 to $37.00 and gave the company an “overweight” rating in a research report on Monday, January 13th. Brookline Capital Management started coverage on Exelixis in a research report on Monday, December 23rd. They set a “buy” rating for the company. BMO Capital Markets cut Exelixis from an “outperform” rating to a “market perform” rating and increased their price target for the stock from $36.00 to $40.00 in a research note on Friday, December 20th. Finally, Morgan Stanley lifted their price objective on shares of Exelixis from $26.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, October 11th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.